Cargando…
Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug
Background. CDRI 97/78 has shown efficacy in animal models of falciparum malaria. The present study is the first in-human phase I trial in healthy volunteers. Methods. The study was conducted in 50 healthy volunteers in a single, ascending dose, randomized, placebo-controlled, double blind design. T...
Autores principales: | Shafiq, N., Rajagopalan, S., Kushwaha, H. N., Mittal, N., Chandurkar, N., Bhalla, A., Kaur, S., Pandhi, P., Puri, G. D., Achuthan, S., Pareek, A., Singh, S. K., Srivastava, J. S., Gaur, S. P. S., Malhotra, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985299/ https://www.ncbi.nlm.nih.gov/pubmed/24800100 http://dx.doi.org/10.1155/2014/372521 |
Ejemplares similares
-
Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97–78 in rat plasma using the HPLC–ESI-MS/MS method: application to drug interaction study
por: Wahajuddin, Muhammad, et al.
Publicado: (2015) -
Assay method for quality control and stability studies of a new antimalarial agent (CDRI 99/411)()
por: Khandelwal, Kiran, et al.
Publicado: (2013) -
Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor
por: Srivastava, Pratima
Publicado: (2012) -
A prospective observational study on different poisoning cases and their outcomes in a tertiary care hospital
por: Mittal, Niti, et al.
Publicado: (2013) -
Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99–411, with long acting prescription antimalarials, lumefantrine and piperaquine
por: Taneja, Isha, et al.
Publicado: (2015)